首页 > 最新文献

Livers最新文献

英文 中文
A Simple Algorithm for Semiquantitative Analysis of Scored Histology Data in the R Environment, on the Example of Murine Non-Alcoholic Steatohepatitis Pharmacotherapy 一种在R环境中对评分组织学数据进行半定量分析的简单算法,以小鼠非酒精性脂肪性肝炎药物治疗为例
Pub Date : 2022-12-09 DOI: 10.3390/livers2040031
V. Prikhodko, V. Karev, Yuriy I. Sysoev, D. Ivkin, S. Okovityi
Despite the high medical and socioeconomic burden of non-alcoholic fatty liver disease (NAFLD), treatments that could effectively reduce histological liver damage in this condition are lacking. As providing only qualitative data is a major limitation of most histological scoring systems, we aimed to develop a simple and straightforward algorithm for semiquantitative analysis of scored histology data using the extended Fisher’s exact test in the R environment. As an illustrative example, we used the effects of L-ornithine L-aspartate (LOLA) and empagliflozin (EMPA) in a 3-month chemical/dietary murine model of NAFLD. 100 C57Bl/6 mice were randomized into 4 groups: Intact (n = 10), Control (NAFLD; n = 30), LOLA (NAFLD + 1.5 g·kg−1 b.w./d LOLA orally; n = 30), and EMPA (NAFLD + 10 mg·kg−1 b.w./d EMPA orally; n = 30). LOLA reduced hepatitis activity (p < 0.05), cholestasis, necrosis, and fibrosis severity (p < 0.01), and EMPA prevented necrosis (p < 0.05) and reduced fibrosis severity (p < 0.01). The statistical approach we suggest can be used as a simple complementary tool for exploratory analysis of scored histology data.
尽管非酒精性脂肪性肝病(NAFLD)的医疗和社会经济负担很高,但缺乏能够有效减少这种情况下组织学肝损伤的治疗方法。由于仅提供定性数据是大多数组织学评分系统的主要限制,我们旨在开发一种简单直接的算法,在R环境中使用扩展的Fisher精确检验对评分的组织学数据进行半定量分析。作为一个说明性的例子,我们在一个3个月的NAFLD化学/饮食小鼠模型中使用了L-天冬氨酸鸟氨酸(LOLA)和恩帕列嗪(EMPA)的作用。将100只C57Bl/6小鼠随机分为4组:完整组(n=10)、对照组(NAFLD;n=30)、LOLA(NAFLD+1.5 g·kg−1 b.w./d口服LOLA;n=30。LOLA降低了肝炎活性(p<0.05)、胆汁淤积、坏死和纤维化严重程度(p<0.01),EMPA预防了坏死(p<0.05)并降低了纤维化严重程度。我们建议的统计方法可以作为一种简单的补充工具,用于对评分的组织学数据进行探索性分析。
{"title":"A Simple Algorithm for Semiquantitative Analysis of Scored Histology Data in the R Environment, on the Example of Murine Non-Alcoholic Steatohepatitis Pharmacotherapy","authors":"V. Prikhodko, V. Karev, Yuriy I. Sysoev, D. Ivkin, S. Okovityi","doi":"10.3390/livers2040031","DOIUrl":"https://doi.org/10.3390/livers2040031","url":null,"abstract":"Despite the high medical and socioeconomic burden of non-alcoholic fatty liver disease (NAFLD), treatments that could effectively reduce histological liver damage in this condition are lacking. As providing only qualitative data is a major limitation of most histological scoring systems, we aimed to develop a simple and straightforward algorithm for semiquantitative analysis of scored histology data using the extended Fisher’s exact test in the R environment. As an illustrative example, we used the effects of L-ornithine L-aspartate (LOLA) and empagliflozin (EMPA) in a 3-month chemical/dietary murine model of NAFLD. 100 C57Bl/6 mice were randomized into 4 groups: Intact (n = 10), Control (NAFLD; n = 30), LOLA (NAFLD + 1.5 g·kg−1 b.w./d LOLA orally; n = 30), and EMPA (NAFLD + 10 mg·kg−1 b.w./d EMPA orally; n = 30). LOLA reduced hepatitis activity (p < 0.05), cholestasis, necrosis, and fibrosis severity (p < 0.01), and EMPA prevented necrosis (p < 0.05) and reduced fibrosis severity (p < 0.01). The statistical approach we suggest can be used as a simple complementary tool for exploratory analysis of scored histology data.","PeriodicalId":74083,"journal":{"name":"Livers","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42242241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
One Carbon Metabolism and S-Adenosylmethionine in Non-Alcoholic Fatty Liver Disease Pathogenesis and Subtypes. 1碳代谢和s -腺苷蛋氨酸在非酒精性脂肪肝发病机制和亚型中的作用。
Pub Date : 2022-12-01 DOI: 10.3390/livers2040020
David Fernández-Ramos, Fernando Lopitz-Otsoa, Oscar Millet, Cristina Alonso, Shelly C Lu, José M Mato

One carbon metabolism (1CM) can be defined as the transfer of a carbon unit from one metabolite to another and its replenishment by different sources of labile methyl-group nutrients: primarily choline, methionine, betaine, and serine. This flow of carbon units allows the biosynthesis of nucleotides, amino acids, formylated methionyl-tRNA, polyamines, glutathione, phospholipids, detoxification reactions, maintenance of the redox status and the concentration of NAD, and methylation reactions including epigenetic modifications. That is, 1CM functions as a nutrient sensor and integrator of cellular metabolism. A critical process in 1CM is the synthesis of S-adenosylmethionine (SAMe), the source of essentially all the hundreds of millions of daily methyl transfer reactions in a cell. This versatility of SAMe imposes a tight control in its synthesis and catabolism. Much of our knowledge concerning 1CM has been gained from studies in the production and prevention of nonalcoholic fatty liver disease (NAFLD). Here, we discuss in detail the function of the most important enzymes for their quantitative contribution to maintaining the flux of carbon units through 1CM in the liver and discuss how alterations in their enzymatic activity contribute to the development of NAFLD. Next, we discuss NAFLD subtypes based on serum lipidomic profiles with different risk of cardiovascular disease. Among the latter, we highlight the so-called subtype A for its serum lipidomic profile phenocopying that of mice deficient in SAMe synthesis and because its high frequency (about 50% of the NAFLD patients).

一次碳代谢(1CM)可以定义为碳单位从一种代谢物转移到另一种代谢物,并通过不同来源的不稳定甲基营养素(主要是胆碱、蛋氨酸、甜菜碱和丝氨酸)进行补充。碳单元的流动允许核苷酸、氨基酸、甲酰化甲硫基trna、多胺、谷胱甘肽、磷脂的生物合成、解毒反应、氧化还原状态和NAD浓度的维持,以及包括表观遗传修饰的甲基化反应。也就是说,1CM作为细胞代谢的营养传感器和积分器。1CM中的一个关键过程是s -腺苷甲硫氨酸(SAMe)的合成,这是细胞中每天数亿个甲基转移反应的基本来源。SAMe的这种多功能性对其合成和分解代谢施加了严格的控制。我们关于1CM的大部分知识都是从非酒精性脂肪性肝病(NAFLD)的产生和预防研究中获得的。在这里,我们详细讨论了最重要的酶的功能,因为它们对维持肝脏中碳单位通过1CM的通量的定量贡献,并讨论了它们的酶活性的改变如何促进NAFLD的发展。接下来,我们讨论基于血清脂质组学特征的NAFLD亚型与不同心血管疾病风险。在后者中,我们强调了所谓的A亚型,因为它的血清脂质组学特征与SAMe合成缺陷小鼠的表型相似,并且因为它的高频率(约占NAFLD患者的50%)。
{"title":"One Carbon Metabolism and <i>S</i>-Adenosylmethionine in Non-Alcoholic Fatty Liver Disease Pathogenesis and Subtypes.","authors":"David Fernández-Ramos,&nbsp;Fernando Lopitz-Otsoa,&nbsp;Oscar Millet,&nbsp;Cristina Alonso,&nbsp;Shelly C Lu,&nbsp;José M Mato","doi":"10.3390/livers2040020","DOIUrl":"https://doi.org/10.3390/livers2040020","url":null,"abstract":"<p><p>One carbon metabolism (1CM) can be defined as the transfer of a carbon unit from one metabolite to another and its replenishment by different sources of labile methyl-group nutrients: primarily choline, methionine, betaine, and serine. This flow of carbon units allows the biosynthesis of nucleotides, amino acids, formylated methionyl-tRNA, polyamines, glutathione, phospholipids, detoxification reactions, maintenance of the redox status and the concentration of NAD, and methylation reactions including epigenetic modifications. That is, 1CM functions as a nutrient sensor and integrator of cellular metabolism. A critical process in 1CM is the synthesis of <i>S</i>-adenosylmethionine (SAMe), the source of essentially all the hundreds of millions of daily methyl transfer reactions in a cell. This versatility of SAMe imposes a tight control in its synthesis and catabolism. Much of our knowledge concerning 1CM has been gained from studies in the production and prevention of nonalcoholic fatty liver disease (NAFLD). Here, we discuss in detail the function of the most important enzymes for their quantitative contribution to maintaining the flux of carbon units through 1CM in the liver and discuss how alterations in their enzymatic activity contribute to the development of NAFLD. Next, we discuss NAFLD subtypes based on serum lipidomic profiles with different risk of cardiovascular disease. Among the latter, we highlight the so-called subtype A for its serum lipidomic profile phenocopying that of mice deficient in SAMe synthesis and because its high frequency (about 50% of the NAFLD patients).</p>","PeriodicalId":74083,"journal":{"name":"Livers","volume":"2 4","pages":"243-257"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9751790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Anti-Metastatic Activity of Tagitinin C from Tithonia diversifolia in a Xenograft Mouse Model of Hepatocellular Carcinoma 鬼针草Tagitinin C在肝癌异种移植小鼠模型中的抗转移活性
Pub Date : 2022-12-01 DOI: 10.3390/livers2040030
Chuan-Yi Lin, May-Hua Liao, Chi-Yu Yang, Chao-Kai Chang, Shih-Mei Hsu, C. Juang, H. Wen
Sesquiterpenoid tagitinin C, present in Tithonia diversifolia leaves, has been known to have anti-hepatoma properties. Therefore, we investigated the anti-metastatic potential of tagitinin C in xenograft models of hepatocellular carcinoma (HCC). We isolated tagitinin C from a methanolic extract of the leaves of T. diversifolia. HepG-2 and Huh 7 hepatoma cells were treated with tagitinin C, and cell viability, migration, and matrix metalloproteinase (MPP) activity were assessed using the 3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide assay, scratch migration assay, and MMP activity assay, respectively. We used magnetic resonance spectroscopy to determine the tumorigenicity of xenografts inoculated with Hep-G2 and Huh 7 cells. Tagitinin C was cytotoxic against Hep-G2 and Huh 7 cells, with IC50 values of 2.0 ± 0.1 µg/mL and 1.2 ± 0.1 µg/mL, respectively, and it showed an anti-metastatic effect in vitro. Additionally, MRS assays revealed that tagitinin C (15 g/mouse/day) reduced the tumorigenicity of Hep-G2 and Huh 7 cell xenografts. Tagitinin C demonstrated significant antitumor and anti-metastatic activity in the two human hepatoma cell lines. Tagitinin C might be used as an alternative or auxiliary therapy for the treatment of HCC, and its effect should be further investigated in clinical settings.
千叶香叶中存在的倍半萜类tagitinin C具有抗肝癌的特性。因此,我们研究了tagitinin C在肝细胞癌(HCC)异种移植模型中的抗转移潜力。我们从三叶草(T.diversifolia)叶的甲醇提取物中分离出tagitinin C。用tagitininC处理HepG-2和Huh7肝癌细胞,并分别用3-(4,5-二甲基硫唑-2-基)-2,5-二苯基溴化四氮唑测定法、划痕迁移测定法和MMP活性测定法评估细胞活力、迁移和基质金属蛋白酶(MPP)活性。我们使用磁共振波谱来确定接种Hep-G2和Huh7细胞的异种移植物的致瘤性。Tagitinin C对Hep-G2和Huh 7细胞具有细胞毒性,IC50值分别为2.0±0.1µg/mL和1.2±0.1µg/mL,在体外显示出抗转移作用。此外,MRS测定显示,tagitinin C(15g/小鼠/天)降低了Hep-G2和Huh 7细胞异种移植物的致瘤性。Tagitinin C在两种人肝癌细胞系中显示出显著的抗肿瘤和抗转移活性。Tagitinin C可能被用作HCC的替代或辅助治疗,其效果应在临床环境中进一步研究。
{"title":"Anti-Metastatic Activity of Tagitinin C from Tithonia diversifolia in a Xenograft Mouse Model of Hepatocellular Carcinoma","authors":"Chuan-Yi Lin, May-Hua Liao, Chi-Yu Yang, Chao-Kai Chang, Shih-Mei Hsu, C. Juang, H. Wen","doi":"10.3390/livers2040030","DOIUrl":"https://doi.org/10.3390/livers2040030","url":null,"abstract":"Sesquiterpenoid tagitinin C, present in Tithonia diversifolia leaves, has been known to have anti-hepatoma properties. Therefore, we investigated the anti-metastatic potential of tagitinin C in xenograft models of hepatocellular carcinoma (HCC). We isolated tagitinin C from a methanolic extract of the leaves of T. diversifolia. HepG-2 and Huh 7 hepatoma cells were treated with tagitinin C, and cell viability, migration, and matrix metalloproteinase (MPP) activity were assessed using the 3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide assay, scratch migration assay, and MMP activity assay, respectively. We used magnetic resonance spectroscopy to determine the tumorigenicity of xenografts inoculated with Hep-G2 and Huh 7 cells. Tagitinin C was cytotoxic against Hep-G2 and Huh 7 cells, with IC50 values of 2.0 ± 0.1 µg/mL and 1.2 ± 0.1 µg/mL, respectively, and it showed an anti-metastatic effect in vitro. Additionally, MRS assays revealed that tagitinin C (15 g/mouse/day) reduced the tumorigenicity of Hep-G2 and Huh 7 cell xenografts. Tagitinin C demonstrated significant antitumor and anti-metastatic activity in the two human hepatoma cell lines. Tagitinin C might be used as an alternative or auxiliary therapy for the treatment of HCC, and its effect should be further investigated in clinical settings.","PeriodicalId":74083,"journal":{"name":"Livers","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41611491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Role of Pyroptosis in Acetaminophen-Induced Hepatotoxicity. 对乙酰氨基酚诱导的肝毒性中的热蛋白沉积作用
Pub Date : 2022-12-01 Epub Date: 2022-12-13 DOI: 10.3390/livers2040032
Hartmut Jaeschke, David S Umbaugh, Anup Ramachandran

Acetaminophen (APAP) is a widely used pain reliever that can cause liver injury or liver failure in response to an overdose. Understanding the mechanisms of APAP-induced cell death is critical for identifying new therapeutic targets. In this respect it was hypothesized that hepatocytes die by oncotic necrosis, apoptosis, necroptosis, ferroptosis and more recently pyroptosis. The latter cell death is characterized by caspase-dependent gasdermin cleavage into a C-terminal and an N-terminal fragment, which forms pores in the plasma membrane. The gasdermin pores can release potassium, interleukin-1β (IL-1β), IL-18, and other small molecules in a sublytic phase, which can be the main function of the pores in certain cell types such as inflammatory cells. Alternatively, the process can progress to full lysis of the cell (pyroptosis) with extensive cell contents release. This review discusses the experimental evidence for the involvement of pyroptosis in APAP hepatotoxicity as well as the arguments against pyroptosis as a relevant mechanism of APAP-induced cell death in hepatocytes. Based on the critical evaluation of the currently available literature and understanding of the pathophysiology, it can be concluded that pyroptotic cell death is unlikely to be a relevant contributor to APAP-induced liver injury.

对乙酰氨基酚(APAP)是一种广泛使用的止痛药,过量服用可导致肝损伤或肝衰竭。了解 APAP 诱导细胞死亡的机制对于确定新的治疗靶点至关重要。在这方面,有人假设肝细胞会通过肿瘤性坏死、凋亡、坏死凋亡、铁凋亡以及最近的热凋亡而死亡。后一种细胞死亡的特点是依赖于 Caspase 的 gasdermin 分裂成 C 端和 N 端片段,并在质膜上形成孔。气孔可在亚溶解阶段释放钾、白细胞介素-1β(IL-1β)、IL-18 和其他小分子,这可能是气孔在某些细胞类型(如炎症细胞)中的主要功能。另外,这一过程也可能发展为细胞的完全裂解(热解),并释放出大量细胞内容物。本综述讨论了参与 APAP 肝毒性的裂解过程的实验证据,以及反对将裂解作为 APAP 诱导肝细胞死亡的相关机制的论据。根据对现有文献的批判性评估和对病理生理学的理解,可以得出结论:热昏迷细胞死亡不太可能是 APAP 诱导肝损伤的相关因素。
{"title":"Role of Pyroptosis in Acetaminophen-Induced Hepatotoxicity.","authors":"Hartmut Jaeschke, David S Umbaugh, Anup Ramachandran","doi":"10.3390/livers2040032","DOIUrl":"10.3390/livers2040032","url":null,"abstract":"<p><p>Acetaminophen (APAP) is a widely used pain reliever that can cause liver injury or liver failure in response to an overdose. Understanding the mechanisms of APAP-induced cell death is critical for identifying new therapeutic targets. In this respect it was hypothesized that hepatocytes die by oncotic necrosis, apoptosis, necroptosis, ferroptosis and more recently pyroptosis. The latter cell death is characterized by caspase-dependent gasdermin cleavage into a C-terminal and an N-terminal fragment, which forms pores in the plasma membrane. The gasdermin pores can release potassium, interleukin-1β (IL-1β), IL-18, and other small molecules in a sublytic phase, which can be the main function of the pores in certain cell types such as inflammatory cells. Alternatively, the process can progress to full lysis of the cell (pyroptosis) with extensive cell contents release. This review discusses the experimental evidence for the involvement of pyroptosis in APAP hepatotoxicity as well as the arguments against pyroptosis as a relevant mechanism of APAP-induced cell death in hepatocytes. Based on the critical evaluation of the currently available literature and understanding of the pathophysiology, it can be concluded that pyroptotic cell death is unlikely to be a relevant contributor to APAP-induced liver injury.</p>","PeriodicalId":74083,"journal":{"name":"Livers","volume":"2 4","pages":"425-435"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10480188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preclinical Experience of the Mayo Spheroid Reservoir Bioartificial Liver (SRBAL) in Management of Acute Liver Failure Mayo球形贮存器生物人工肝(SRBAL)治疗急性肝功能衰竭的临床前经验
Pub Date : 2022-11-02 DOI: 10.3390/livers2040029
P. Felgendreff, Mohammad Tharwat, Seyed M. Hosseiniasl, B. Amiot, Anna Minshew, A. A. Rmilah, Xiaoye Sun, Dustin J. Duffy, W. Kremers, S. Nyberg
The Spheroid Reservoir Bioartificial Liver (SRBAL) is an innovative treatment option for acute liver failure (ALF). This extracorporeal support device, which provides detoxification and other liver functions using high-density culture of porcine hepatocyte spheroids, has been reported in three randomized large animal studies. A meta-analysis of these three preclinical studies was performed to establish efficacy of SRBAL treatment in terms of survival benefit and neuroprotective effect. The studies included two hepatotoxic drug models of ALF (D-galactosamine, α-amanitin/lipopolysaccharide) or a liver resection model (85% hepatectomy) in pigs or monkeys. The SRBAL treatment was started in three different settings starting at 12 h, 24 h or 48 h after induction of ALF; comparisons were made with two similar control groups in each model. SRBAL therapy was associated with significant survival and neuroprotective benefits in all three animal models of ALF. The benefits of therapy were dose dependent with the most effective configuration of SRBAL being continuous treatment of 24 h duration and dose of 200 g of porcine hepatic spheroids. Future clinical testing of SRBAL in patients with ALF appears warranted.
球形储层生物人工肝(SRBAL)是一种治疗急性肝衰竭(ALF)的创新选择。这种体外支持装置,通过高密度培养猪肝细胞球体提供解毒和其他肝脏功能,已在三个随机大型动物研究中报道。对这三项临床前研究进行荟萃分析,以确定SRBAL治疗在生存获益和神经保护作用方面的有效性。研究包括猪或猴子的两种肝毒性药物ALF (d -半乳糖胺,α-amanitin/脂多糖)模型和肝切除模型(85%肝切除)。SRBAL处理在ALF诱导后12小时、24小时和48小时三种不同的情况下开始;每个模型与两个相似的对照组进行比较。在所有三种ALF动物模型中,SRBAL治疗均与显著的生存和神经保护益处相关。治疗的益处是剂量依赖性的,SRBAL最有效的配置是持续治疗24小时,剂量为200 g猪肝球。SRBAL在ALF患者中的未来临床试验似乎是有必要的。
{"title":"Preclinical Experience of the Mayo Spheroid Reservoir Bioartificial Liver (SRBAL) in Management of Acute Liver Failure","authors":"P. Felgendreff, Mohammad Tharwat, Seyed M. Hosseiniasl, B. Amiot, Anna Minshew, A. A. Rmilah, Xiaoye Sun, Dustin J. Duffy, W. Kremers, S. Nyberg","doi":"10.3390/livers2040029","DOIUrl":"https://doi.org/10.3390/livers2040029","url":null,"abstract":"The Spheroid Reservoir Bioartificial Liver (SRBAL) is an innovative treatment option for acute liver failure (ALF). This extracorporeal support device, which provides detoxification and other liver functions using high-density culture of porcine hepatocyte spheroids, has been reported in three randomized large animal studies. A meta-analysis of these three preclinical studies was performed to establish efficacy of SRBAL treatment in terms of survival benefit and neuroprotective effect. The studies included two hepatotoxic drug models of ALF (D-galactosamine, α-amanitin/lipopolysaccharide) or a liver resection model (85% hepatectomy) in pigs or monkeys. The SRBAL treatment was started in three different settings starting at 12 h, 24 h or 48 h after induction of ALF; comparisons were made with two similar control groups in each model. SRBAL therapy was associated with significant survival and neuroprotective benefits in all three animal models of ALF. The benefits of therapy were dose dependent with the most effective configuration of SRBAL being continuous treatment of 24 h duration and dose of 200 g of porcine hepatic spheroids. Future clinical testing of SRBAL in patients with ALF appears warranted.","PeriodicalId":74083,"journal":{"name":"Livers","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44158276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FYB2 Is a Potential Prognostic Biomarker for Hepatocellular Carcinoma FYB2是肝细胞癌的潜在预后生物标志物
Pub Date : 2022-11-02 DOI: 10.3390/livers2040027
Yifang Qu, X. Shen, Xinpei Yuan, Bing Lu
FYB2 (also known as C1orf168 or ARAP) is an adaptor protein involved in T-cell receptor (TCR)-mediated T-cell activation and adhesion. However, the correlation of FYB2 with prognosis and cancer needs further investigation. In this study, we analyzed the expression levels of FYB2 in hepatocellular carcinoma (LIHC) tumor tissues and correlated it with the pathological stages, survival outcomes, and tumor grades. We found that the expression of FYB2 was significantly downregulated in LIHC. Low FYB2 level leading to weak survival outcomes is linked with advanced tumor grades and elevated pathological stages. Cox regression analysis showed that FYB2 and AJCC-M stages can be used as independent prognostic factors for LIHC. GSEA analysis revealed that FYB2 would be notably correlated with the cellular metabolism-related pathways and particularly involved in the regulation of cancer-related pathways. Single-cell transcriptome analysis revealed that FYB2-positive cells were mainly distributed in hepatocytes, and compared with other cells, the upregulated genes of these cells were mainly enriched in metabolism-related functions. The results of the spatial transcriptome revealed that the expression of FYB2 in the adjacent area was higher than in the tumor area. These results showed that FYB2 is likely to be a new prognostic biomarker in LIHC and would help provide individual treatment decisions for LIHC patients.
FYB2(也称为C1orf168或ARAP)是一种连接蛋白,参与t细胞受体(TCR)介导的t细胞活化和粘附。但FYB2与预后及肿瘤的相关性有待进一步研究。在本研究中,我们分析了FYB2在肝细胞癌(LIHC)肿瘤组织中的表达水平,并将其与病理分期、生存结局和肿瘤分级进行了相关性分析。我们发现在LIHC中FYB2的表达明显下调。低FYB2水平导致较弱的生存结果与晚期肿瘤分级和病理分期升高有关。Cox回归分析显示FYB2和AJCC-M分期可作为LIHC的独立预后因素。GSEA分析显示FYB2与细胞代谢相关通路显著相关,尤其参与肿瘤相关通路的调控。单细胞转录组分析显示,fyb2阳性细胞主要分布在肝细胞中,与其他细胞相比,这些细胞的上调基因主要富集于代谢相关功能。空间转录组结果显示FYB2在邻近区域的表达高于肿瘤区域。这些结果表明FYB2可能是LIHC中新的预后生物标志物,并有助于为LIHC患者提供个性化的治疗决策。
{"title":"FYB2 Is a Potential Prognostic Biomarker for Hepatocellular Carcinoma","authors":"Yifang Qu, X. Shen, Xinpei Yuan, Bing Lu","doi":"10.3390/livers2040027","DOIUrl":"https://doi.org/10.3390/livers2040027","url":null,"abstract":"FYB2 (also known as C1orf168 or ARAP) is an adaptor protein involved in T-cell receptor (TCR)-mediated T-cell activation and adhesion. However, the correlation of FYB2 with prognosis and cancer needs further investigation. In this study, we analyzed the expression levels of FYB2 in hepatocellular carcinoma (LIHC) tumor tissues and correlated it with the pathological stages, survival outcomes, and tumor grades. We found that the expression of FYB2 was significantly downregulated in LIHC. Low FYB2 level leading to weak survival outcomes is linked with advanced tumor grades and elevated pathological stages. Cox regression analysis showed that FYB2 and AJCC-M stages can be used as independent prognostic factors for LIHC. GSEA analysis revealed that FYB2 would be notably correlated with the cellular metabolism-related pathways and particularly involved in the regulation of cancer-related pathways. Single-cell transcriptome analysis revealed that FYB2-positive cells were mainly distributed in hepatocytes, and compared with other cells, the upregulated genes of these cells were mainly enriched in metabolism-related functions. The results of the spatial transcriptome revealed that the expression of FYB2 in the adjacent area was higher than in the tumor area. These results showed that FYB2 is likely to be a new prognostic biomarker in LIHC and would help provide individual treatment decisions for LIHC patients.","PeriodicalId":74083,"journal":{"name":"Livers","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44767772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liver Fibrosis, Liver Cancer, and Advances in Therapeutic Approaches 肝纤维化、肝癌及治疗方法的进展
Pub Date : 2022-11-02 DOI: 10.3390/livers2040028
Indu G. Rajapaksha
Chronic liver diseases (CLDs) that lead to hepatic fibrosis, cirrhosis, and/or hepatocellular carcinoma (HCC) have become a major cause of illness and death worldwide. The main causative factors for CLDs are chronic viral infections, excessive alcohol consumption, non-alcoholic fatty liver disease (NAFLD), and cholestatic diseases. The primary approach to managing cirrhosis should be removing the causative agent, and the secondary approach should address fibrogenesis. Liver cancer is also a leading cause of death worldwide, and many therapeutic approaches exist to treat the disease. However, liver transplantation remains the last treatment option for cirrhosis and liver cancer. Thus, this review discusses the pathophysiology of liver fibrosis, its progression to cirrhosis and HCC, and current therapeutic options available to treat the diseases with potential therapeutic options that will be available in the near future.
导致肝纤维化、肝硬化和/或肝细胞癌(HCC)的慢性肝病(CLDs)已成为全球疾病和死亡的主要原因。CLDs的主要致病因素是慢性病毒感染、过度饮酒、非酒精性脂肪性肝病(NAFLD)和胆汁淤积性疾病。治疗肝硬化的主要方法是清除病原体,其次是解决纤维化问题。肝癌也是世界范围内死亡的主要原因,目前有许多治疗方法可以治疗这种疾病。然而,肝移植仍然是肝硬化和肝癌的最后治疗选择。因此,本综述讨论了肝纤维化的病理生理学,其向肝硬化和HCC的进展,以及目前可用于治疗疾病的治疗方案,以及在不久的将来可获得的潜在治疗方案。
{"title":"Liver Fibrosis, Liver Cancer, and Advances in Therapeutic Approaches","authors":"Indu G. Rajapaksha","doi":"10.3390/livers2040028","DOIUrl":"https://doi.org/10.3390/livers2040028","url":null,"abstract":"Chronic liver diseases (CLDs) that lead to hepatic fibrosis, cirrhosis, and/or hepatocellular carcinoma (HCC) have become a major cause of illness and death worldwide. The main causative factors for CLDs are chronic viral infections, excessive alcohol consumption, non-alcoholic fatty liver disease (NAFLD), and cholestatic diseases. The primary approach to managing cirrhosis should be removing the causative agent, and the secondary approach should address fibrogenesis. Liver cancer is also a leading cause of death worldwide, and many therapeutic approaches exist to treat the disease. However, liver transplantation remains the last treatment option for cirrhosis and liver cancer. Thus, this review discusses the pathophysiology of liver fibrosis, its progression to cirrhosis and HCC, and current therapeutic options available to treat the diseases with potential therapeutic options that will be available in the near future.","PeriodicalId":74083,"journal":{"name":"Livers","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47757217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Synergistic Anti-tumor Effect of Palmitoylcarnitine and Dasatinib in Liver Cancer 棕榈酰肉碱和达沙替尼对癌症的协同抗肿瘤作用
Pub Date : 2022-11-01 DOI: 10.3390/livers2040026
Ragini Singh, Shu-Li Cheng, Qinghua Zeng, Santosh Kumar, Carlos Marques
Hepatocellular carcinoma (HCC) is the third major cause of cancer-related death worldwide and responds positively to tyrosine kinase inhibitors (TKIs). Dasatinib (Das) is an Src/Abl family kinase and has been successfully utilized in the treatment of various cancers. Cancer cells are known to limit their oxidative phosphorylation to minimize oxidative stress. Palmitoylcarnitine (Pcar) incubation triggers mitochondria-mediated apoptosis in cancer cells by increasing the mitochondrial respiration rate. It stimulates the H2O2 production in cancer cells and thus induces oxidative stress. Thus, considering the above observations, the combined effect of Pcar and Das on HepG2, liver cancer cells has been evaluated in the present study. Results demonstrated that combined exposure to Pcar and dasatinib inhibited cell growth, proliferation, and invasion efficiency of cancerous cells more than single-drug treatment. Further, cells undergo membrane depolarization and caspase-dependent apoptosis upon exposure to combined treatment. In addition, in vivo study showed that Pcar and dasatinib treatment reduced the tumor size in mice more significantly than single-drug treatment. Thus, considering the above remarks, combined therapy of Pcar and dasatinib may serve as a potential candidate in the treatment of liver cancer in human and animal tissues.
肝细胞癌(HCC)是全球癌症相关死亡的第三大原因,对酪氨酸激酶抑制剂(TKI)有积极反应。达沙替尼(Das)是一种Src/Abl家族激酶,已成功用于治疗各种癌症。已知癌症细胞限制其氧化磷酸化以最小化氧化应激。棕榈酰肉碱(Pcar)孵育通过增加线粒体呼吸速率,触发癌症细胞线粒体介导的凋亡。它刺激癌症细胞中H2O2的产生,从而诱导氧化应激。因此,考虑到上述观察结果,在本研究中评估了Pcar和Das对HepG2、癌症细胞的联合作用。结果表明,Pcar和达沙替尼联合暴露比单一药物治疗更能抑制癌细胞的生长、增殖和侵袭效率。此外,细胞在暴露于联合治疗后经历膜去极化和胱天蛋白酶依赖性凋亡。此外,体内研究表明,Pcar和达沙替尼治疗比单药治疗更显著地缩小了小鼠的肿瘤大小。因此,考虑到上述备注,Pcar和达沙替尼的联合治疗可以作为治疗人类和动物组织中的肝癌的潜在候选。
{"title":"Synergistic Anti-tumor Effect of Palmitoylcarnitine and Dasatinib in Liver Cancer","authors":"Ragini Singh, Shu-Li Cheng, Qinghua Zeng, Santosh Kumar, Carlos Marques","doi":"10.3390/livers2040026","DOIUrl":"https://doi.org/10.3390/livers2040026","url":null,"abstract":"Hepatocellular carcinoma (HCC) is the third major cause of cancer-related death worldwide and responds positively to tyrosine kinase inhibitors (TKIs). Dasatinib (Das) is an Src/Abl family kinase and has been successfully utilized in the treatment of various cancers. Cancer cells are known to limit their oxidative phosphorylation to minimize oxidative stress. Palmitoylcarnitine (Pcar) incubation triggers mitochondria-mediated apoptosis in cancer cells by increasing the mitochondrial respiration rate. It stimulates the H2O2 production in cancer cells and thus induces oxidative stress. Thus, considering the above observations, the combined effect of Pcar and Das on HepG2, liver cancer cells has been evaluated in the present study. Results demonstrated that combined exposure to Pcar and dasatinib inhibited cell growth, proliferation, and invasion efficiency of cancerous cells more than single-drug treatment. Further, cells undergo membrane depolarization and caspase-dependent apoptosis upon exposure to combined treatment. In addition, in vivo study showed that Pcar and dasatinib treatment reduced the tumor size in mice more significantly than single-drug treatment. Thus, considering the above remarks, combined therapy of Pcar and dasatinib may serve as a potential candidate in the treatment of liver cancer in human and animal tissues.","PeriodicalId":74083,"journal":{"name":"Livers","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47434927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is There a Place for Somatostatin Analogues for the Systemic Treatment of Hepatocellular Carcinoma in the Immunotherapy Era? 在免疫治疗时代,生长抑素类似物在肝细胞癌的全身治疗中有一席之地吗?
Pub Date : 2022-10-18 DOI: 10.3390/livers2040024
E. Kouroumalis, Ioannis Tsomidis, A. Voumvouraki
Patients with advanced hepatocellular carcinoma (HCC) have a very limited survival rate even after the recent inclusion of kinase inhibitors or immune checkpoint inhibitors in the therapeutic armamentarium. A significant problem with the current proposed therapies is the considerable cost of treatment that may be a serious obstacle in low- and middle-income countries. Implementation of somatostatin analogues (SSAs) has the potential to overcome this obstacle, but due to some negative studies their extensive evaluation came to a halt. However, experimental evidence, both in vitro and in vivo, has revealed various mechanisms of the anti-tumor effects of these analogues, including inhibition of cancer cell proliferation and angiogenesis and induction of apoptosis. Favorable indirect effects such as inhibition of liver inflammation and fibrosis and influence on macrophage-mediated innate immunity have also been noted and are presented in this review. Furthermore, the clinical application of SSAs is both presented and compared with clinical trials of kinase and immune checkpoint inhibitors (ICIs). No direct trials have been performed to compare survival in the same cohort of patients, but the cost of treatment with SSAs is a fraction compared to the other modalities and with significantly less serious side effects. As in immunotherapy, patients with viral HCC (excluding alcoholics), as well as Barcelona stage B or C and Child A patients, are the best candidates, since they usually have a survival prospect of at least 6 months, necessary for optimum results. Reasons for treatment failures are also discussed and further research is proposed.
即使在最近将激酶抑制剂或免疫检查点抑制剂纳入治疗药物后,晚期肝细胞癌(HCC)患者的生存率也非常有限。目前拟议的疗法的一个重大问题是治疗费用高昂,这可能是中低收入国家的一个严重障碍。生长抑素类似物(SSAs)的实施有可能克服这一障碍,但由于一些负面研究,他们的广泛评估停止了。然而,体外和体内的实验证据揭示了这些类似物抗肿瘤作用的各种机制,包括抑制癌症细胞增殖和血管生成以及诱导细胞凋亡。有利的间接作用,如抑制肝脏炎症和纤维化,以及对巨噬细胞介导的先天免疫的影响也已被注意到,并在本文中介绍。此外,还介绍了SSAs的临床应用,并与激酶和免疫检查点抑制剂(ICIs)的临床试验进行了比较。目前还没有进行直接的试验来比较同一队列患者的生存率,但与其他模式相比,SSA的治疗成本只是一小部分,副作用明显较轻。与免疫疗法一样,病毒性HCC患者(不包括酗酒者),以及巴塞罗那B期或C期和儿童A期患者是最好的候选者,因为他们通常有至少6个月的生存前景,这是获得最佳结果所必需的。还讨论了治疗失败的原因,并提出了进一步的研究建议。
{"title":"Is There a Place for Somatostatin Analogues for the Systemic Treatment of Hepatocellular Carcinoma in the Immunotherapy Era?","authors":"E. Kouroumalis, Ioannis Tsomidis, A. Voumvouraki","doi":"10.3390/livers2040024","DOIUrl":"https://doi.org/10.3390/livers2040024","url":null,"abstract":"Patients with advanced hepatocellular carcinoma (HCC) have a very limited survival rate even after the recent inclusion of kinase inhibitors or immune checkpoint inhibitors in the therapeutic armamentarium. A significant problem with the current proposed therapies is the considerable cost of treatment that may be a serious obstacle in low- and middle-income countries. Implementation of somatostatin analogues (SSAs) has the potential to overcome this obstacle, but due to some negative studies their extensive evaluation came to a halt. However, experimental evidence, both in vitro and in vivo, has revealed various mechanisms of the anti-tumor effects of these analogues, including inhibition of cancer cell proliferation and angiogenesis and induction of apoptosis. Favorable indirect effects such as inhibition of liver inflammation and fibrosis and influence on macrophage-mediated innate immunity have also been noted and are presented in this review. Furthermore, the clinical application of SSAs is both presented and compared with clinical trials of kinase and immune checkpoint inhibitors (ICIs). No direct trials have been performed to compare survival in the same cohort of patients, but the cost of treatment with SSAs is a fraction compared to the other modalities and with significantly less serious side effects. As in immunotherapy, patients with viral HCC (excluding alcoholics), as well as Barcelona stage B or C and Child A patients, are the best candidates, since they usually have a survival prospect of at least 6 months, necessary for optimum results. Reasons for treatment failures are also discussed and further research is proposed.","PeriodicalId":74083,"journal":{"name":"Livers","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45566965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Role of Oxidative Stress in Liver Disorders 氧化应激在肝脏疾病中的作用
Pub Date : 2022-10-14 DOI: 10.3390/livers2040023
L. Conde de la Rosa, Leire Goicoechea, S. Torres, C. Garcia-Ruiz, J. Fernandez-Checa
Oxygen is vital for life as it is required for many different enzymatic reactions involved in intermediate metabolism and xenobiotic biotransformation. Moreover, oxygen consumption in the electron transport chain of mitochondria is used to drive the synthesis of ATP to meet the energetic demands of cells. However, toxic free radicals are generated as byproducts of molecular oxygen consumption. Oxidative stress ensues not only when the production of reactive oxygen species (ROS) exceeds the endogenous antioxidant defense mechanism of cells, but it can also occur as a consequence of an unbalance between antioxidant strategies. Given the important role of hepatocytes in the biotransformation and metabolism of xenobiotics, ROS production represents a critical event in liver physiology, and increasing evidence suggests that oxidative stress contributes to the development of many liver diseases. The present review, which is part of the special issue “Oxidant stress in Liver Diseases”, aims to provide an overview of the sources and targets of ROS in different liver diseases and highlights the pivotal role of oxidative stress in cell death. In addition, current antioxidant therapies as treatment options for such disorders and their limitations for future trial design are discussed.
氧对生命至关重要,因为它是许多不同的酶反应所必需的,包括中间代谢和异种生物转化。此外,线粒体电子传递链中的氧气消耗被用来驱动ATP的合成,以满足细胞的能量需求。然而,有毒自由基是作为分子氧消耗的副产物产生的。氧化应激不仅发生在活性氧(ROS)的产生超过细胞内源性抗氧化防御机制时,也可能发生在抗氧化策略不平衡的情况下。鉴于肝细胞在异种生物转化和代谢中的重要作用,ROS的产生是肝脏生理的一个关键事件,越来越多的证据表明氧化应激有助于许多肝脏疾病的发展。本综述是特刊“肝脏疾病中的氧化应激”的一部分,旨在概述不同肝脏疾病中ROS的来源和靶点,并强调氧化应激在细胞死亡中的关键作用。此外,本文还讨论了目前抗氧化疗法作为此类疾病的治疗选择及其在未来试验设计中的局限性。
{"title":"Role of Oxidative Stress in Liver Disorders","authors":"L. Conde de la Rosa, Leire Goicoechea, S. Torres, C. Garcia-Ruiz, J. Fernandez-Checa","doi":"10.3390/livers2040023","DOIUrl":"https://doi.org/10.3390/livers2040023","url":null,"abstract":"Oxygen is vital for life as it is required for many different enzymatic reactions involved in intermediate metabolism and xenobiotic biotransformation. Moreover, oxygen consumption in the electron transport chain of mitochondria is used to drive the synthesis of ATP to meet the energetic demands of cells. However, toxic free radicals are generated as byproducts of molecular oxygen consumption. Oxidative stress ensues not only when the production of reactive oxygen species (ROS) exceeds the endogenous antioxidant defense mechanism of cells, but it can also occur as a consequence of an unbalance between antioxidant strategies. Given the important role of hepatocytes in the biotransformation and metabolism of xenobiotics, ROS production represents a critical event in liver physiology, and increasing evidence suggests that oxidative stress contributes to the development of many liver diseases. The present review, which is part of the special issue “Oxidant stress in Liver Diseases”, aims to provide an overview of the sources and targets of ROS in different liver diseases and highlights the pivotal role of oxidative stress in cell death. In addition, current antioxidant therapies as treatment options for such disorders and their limitations for future trial design are discussed.","PeriodicalId":74083,"journal":{"name":"Livers","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44904998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 19
期刊
Livers
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1